Description: Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.
Home Page: www.resverlogix.com
4820 Richard Road SW
Calgary,
AB
T3E 6L1
Canada
Phone:
403 254 9252
Officers
| Name | Title |
|---|---|
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer |
| Dr. Jan O. Johansson M.D., Ph.D. | Sr. VP of Medical Affairs |
| Dr. Michael Sweeney M.D. | Sr. VP of Clinical Devel. |
| Sarah Zapotichny | Director of Investor Relations & Corp. Communications |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 22 |